Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic neoplasm. Surgery is the factual curative option, but most patients present with advanced disease. In order to increase resectability, results of neoadjuvant chemotherapy (NAC) on metastatic disease were extrapolated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fossaert, Violette, Mimmo, Antonio, Rhaiem, Rami, Rached, Linda J., Brasseur, Mathilde, Brugel, Mathias, Pegoraro, Francesca, Sanchez, Stephane, Bouché, Olivier, Kianmanesh, Reza, Piardi, Tullio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640996/
https://www.ncbi.nlm.nih.gov/pubmed/36387257
http://dx.doi.org/10.3389/fonc.2022.980659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640996/
https://www.ncbi.nlm.nih.gov/pubmed/36387257
http://dx.doi.org/10.3389/fonc.2022.980659

Ejemplares similares